Literature DB >> 3164231

Prognostic factors in osteosarcomas. A regression analysis.

S M Bentzen1, H S Poulsen, S Kaae, O M Jensen, H Johansen, H T Mouridsen, S Daugaard, C Arnoldi.   

Abstract

A multivariate regression analysis of survival data, using the Cox proportional hazards model (PHM), was performed on the retrospective material of 184 osteosarcoma patients treated at the Aarhus and Copenhagen oncology centers, Denmark, from 1963 to 1984. All patients were previously untreated. Radical surgery, in general ablative when possible, was the primary treatment goal throughout this period. A number of clinical and pathologic variables were tested in the model to elucidate their prognostic importance. Tumors localized to the trunk, pelvis, or femur, and symptom duration of less than 6 months were poor prognostic signs. Tumors dominated by fibroblastic cells and a patient age of approximately 25 to 30 years were associated with an especially good prognosis. The prognosis worsened with advancing age. Children, adolescents, and adults ages 5 to 25 years had significantly poorer prognosis than young adults 25 to 30 years of age. Sex, radiologic appearance, and year of referral had no significant prognostic value in this series. Based on the regression model, a prognostic index is derived and survival is calculated for a good and a poor prognostic case. The overall 10-year survival with one standard deviation was 28.6 +/- 3.5%. Cancer deaths continue to occur 10 years after initial treatment, and the estimated hazard rate is still four times greater than that of a sex- and age-matched group of healthy individuals.

Entities:  

Mesh:

Year:  1988        PMID: 3164231     DOI: 10.1002/1097-0142(19880701)62:1<194::aid-cncr2820620129>3.0.co;2-8

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

1.  Extraosseous sarcoma. A case report.

Authors:  D H Vaquero; M C Suarez; I R Contreras; J V Alonso
Journal:  Int Orthop       Date:  1990       Impact factor: 3.075

2.  Local growth and the prognosis of osteosarcoma.

Authors:  P Wuisman; W F Enneking; A Roesner
Journal:  Int Orthop       Date:  1992       Impact factor: 3.075

3.  Expression change of ezrin as a prognostic factor in primary osteosarcoma.

Authors:  Yao Fei Wang; Jing Nan Shen; Xian Biao Xie; Jin Wang; Gang Huang
Journal:  Med Oncol       Date:  2010-09-22       Impact factor: 3.064

4.  Age as a prognostic factor for patients with osteosarcoma: an analysis of 438 patients.

Authors:  Matthew T Harting; Kevin P Lally; Richard J Andrassy; Ara A Vaporciyan; Charles S Cox; Andrea Hayes-Jordan; Martin L Blakely
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-27       Impact factor: 4.553

5.  Biopsy technique in the treatment of osteosarcoma.

Authors:  J A Cara del Rosal; J Cañadell
Journal:  Int Orthop       Date:  1994       Impact factor: 3.075

6.  Intraarterial chemotherapy for extremity osteosarcoma and MFH in adults.

Authors:  Ronald R Hugate; Ross M Wilkins; Cynthia M Kelly; Walt Madsen; Ioana Hinshaw; Anne B Camozzi
Journal:  Clin Orthop Relat Res       Date:  2008-04-25       Impact factor: 4.176

7.  Clinical value of ezrin expression in primary osteosarcoma.

Authors:  Chan Kim; Eunah Shin; Soojung Hong; Hong Jae Chon; Hye Ryun Kim; Jung Ryun Ahn; Min Hee Hong; Woo Ick Yang; Jae Kyung Roh; Sun Young Rha
Journal:  Cancer Res Treat       Date:  2009-09-28       Impact factor: 4.679

8.  Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation.

Authors:  Flemming Brandt Sorensen; Kenneth Jensen; Michael Vaeth; Henrik Hager; Anette Mariane Daa Funder; Akmal Safwat; Johnny Keller; Mariann Christensen
Journal:  Sarcoma       Date:  2009-02-25

Review 9.  mtDNA Heteroplasmy: Origin, Detection, Significance, and Evolutionary Consequences.

Authors:  Maria-Eleni Parakatselaki; Emmanuel D Ladoukakis
Journal:  Life (Basel)       Date:  2021-06-29

10.  miR-183 inhibits the metastasis of osteosarcoma via downregulation of the expression of Ezrin in F5M2 cells.

Authors:  Haien Zhao; Mingjun Guo; Guangyi Zhao; Qiong Ma; Baoan Ma; Xiuchun Qiu; Qingyu Fan
Journal:  Int J Mol Med       Date:  2012-08-24       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.